Buy Kalydeco (ivacaftor) Online

What is Kalydeco (ivacaftor) used for?
Kalydeco (ivacaftor) is intended for patients aged 4 months and older who have cystic fibrosis (CF) and possess at least one mutation in their CF gene that responds to Kalydeco. It is available in tablet form, with each tablet containing 150 mg of ivacaftor.

How does Kalydeco (ivacaftor) work?
Cystic Fibrosis (CF) is a severe genetic disorder characterized by the accumulation of thick mucus in the lungs, digestive tract, and other body parts. This leads to significant respiratory and digestive problems, as well as complications such as infections and diabetes. Mutations in the CFTR gene are responsible for CF. This gene encodes a protein known as ‘cystic-fibrosis transmembrane conductance regulator’ (CFTR), which plays a role in regulating mucus and digestive juice production. These mutations either reduce the number of CFTR protein channels on cell surfaces or disrupt their functioning. These channels are vital for transporting ions (charged atoms and molecules) in and out of cells. When these channels are defective, mucus and digestive juices can become excessively thick and sticky.

Kalydeco (ivacaftor) enhances the activity of impaired CFTR proteins, facilitating ion transport. This action helps reduce CF symptoms by making mucus and digestive juice less thick.

Where has Kalydeco (ivacaftor) been approved?
Kalydeco (ivacaftor) has been approved for the treatment of CF patients with CFTR gene mutations by:

– The Food and Drug Administration (FDA) in the USA on January 31, 2012.
– The European Medical Agency (EMA) in the European Union on August 6, 2012.

Please note that this medication may have received approval in regions beyond the ones mentioned. If you have inquiries about its approval in a specific country, please feel free to contact our support team.

How is Kalydeco (ivacaftor) administered?
The standard dosage for Kalydeco (ivacaftor) is as follows:

For use as monotherapy in patients older than 4 months:
– Taken orally twice a day.
– One tablet should be taken every 12 hours with food containing fat.

In combination with tezacaftor/ivacaftor for adults and adolescents aged 6 and older:
– Taken orally once a day.
– One tezacaftor 100 mg/ivacaftor 150 mg tablet is taken orally in the morning, and one Kalydeco (ivacaftor) tablet is taken in the evening approximately 12 hours apart with food containing fat.

The dose of Kalydeco (ivacaftor) should be adjusted for:

– One 150 mg ivacaftor tablet once daily for patients with moderate hepatic impairment.
– One 150 mg ivacaftor tablet every other day for patients with severe hepatic impairment. Dosing intervals should be adapted based on clinical response and tolerability.

The dose of Kalydeco (ivacaftor) must be modified to:

– One tablet twice a week when co-administered with strong CYP3A inhibitors.
– One tablet once daily when co-administered with moderate CYP3A inhibitors.

For complete information about Kalydeco (ivacaftor) dosage and administration, please refer to the official prescribing information listed in our resources section.

Note: Consult with your treating doctor for personalized dosing and potential drug interactions.

Are there any known side effects or adverse reactions to Kalydeco (ivacaftor)?
Common adverse reactions listed in the prescribing information include:

– Upper respiratory tract infection
– Nasopharyngitis (contagious throat disease)
– Headache
– Dizziness
– Oropharyngeal pain
– Nasal congestion
– Abdominal pain
– Diarrhea
– Elevated liver enzymes
– Rash
– Presence of bacteria in mucus.